Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · IEX Real-Time Price · USD
1.860
-0.110 (-5.58%)
At close: Jul 2, 2024, 4:00 PM
1.900
+0.040 (2.15%)
After-hours: Jul 2, 2024, 4:37 PM EDT
Mersana Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for MRSN stock have an average target of 5.57, with a low estimate of 1.00 and a high estimate of 9.00. The average target predicts an increase of 199.46% from the current stock price of 1.86.
Analyst Consensus: Buy
* Price targets were last updated on Mar 19, 2024.
Analyst Ratings
The average analyst rating for MRSN stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Hold | 5 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Sell → Hold Upgrades $5 | Sell → Hold | Upgrades | $5 | +168.82% | Mar 19, 2024 |
| Wedbush | Wedbush | Hold → Buy Upgrades $2 → $7 | Hold → Buy | Upgrades | $2 → $7 | +276.34% | Feb 29, 2024 |
| Truist Securities | Truist Securities | Hold → Strong Buy Upgrades $9 | Hold → Strong Buy | Upgrades | $9 | +383.87% | Feb 29, 2024 |
| Baird | Baird | Hold Maintains $1 → $5 | Hold | Maintains | $1 → $5 | +168.82% | Feb 29, 2024 |
| Guggenheim | Guggenheim | Hold → Strong Buy Upgrades $7 | Hold → Strong Buy | Upgrades | $7 | +276.34% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
40.49M
from 36.86M
Increased by 9.86%
Revenue Next Year
32.61M
from 40.49M
Decreased by -19.46%
EPS This Year
-0.65
from -1.48
EPS Next Year
-0.74
from -0.65
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 73.5M | 52.5M | 78.8M | 42.0M | 373.9M |
| Avg | 40.5M | 32.6M | 33.2M | 30.5M | 283.6M |
| Low | 9.1M | n/a | n/a | 18.0M | 196.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 99.4% | 29.7% | 141.5% | 26.7% | 1,125.5% |
| Avg | 9.9% | -19.5% | 1.7% | -8.0% | 829.5% |
| Low | -75.4% | - | - | -45.7% | 542.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.26 | -0.39 | -0.27 | -0.57 |
| Avg | -0.65 | -0.74 | -0.75 | -0.55 |
| Low | -0.89 | -0.88 | -1.03 | -0.53 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.